Technical Analysis for REPL - Replimune Group, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 10.35 | -1.24% | -0.13 |
REPL closed down 1.24 percent on Friday, July 26, 2024, on 47 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Aug 1
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | -1.24% | |
| Up 3 Days in a Row | Strength | -1.24% | |
| Multiple of Ten Bullish | Other | 0.98% | |
| Wide Bands | Range Expansion | 0.98% | |
| MACD Bearish Signal Line Cross | Bearish | 3.09% | |
| Multiple of Ten Bullish | Other | 3.09% |
| Alert | Time |
|---|---|
| Possible NR7 | about 13 hours ago |
| Possible Inside Day | about 13 hours ago |
| Down 2 % | about 14 hours ago |
| Fell Below 10 DMA | about 14 hours ago |
| 10 DMA Support | about 16 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/01/2024
Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatment Virotherapy Immunotherapy Products Oncolytic Virus Experimental Cancer Treatments Transgene Sa Akseli Hemminki Rp1
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatment Virotherapy Immunotherapy Products Oncolytic Virus Experimental Cancer Treatments Transgene Sa Akseli Hemminki Rp1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.6 |
| 52 Week Low | 4.92 |
| Average Volume | 1,314,733 |
| 200-Day Moving Average | 8.79 |
| 50-Day Moving Average | 8.07 |
| 20-Day Moving Average | 9.63 |
| 10-Day Moving Average | 10.34 |
| Average True Range | 0.67 |
| RSI (14) | 61.24 |
| ADX | 30.71 |
| +DI | 32.72 |
| -DI | 15.25 |
| Chandelier Exit (Long, 3 ATRs) | 9.30 |
| Chandelier Exit (Short, 3 ATRs) | 9.88 |
| Upper Bollinger Bands | 11.47 |
| Lower Bollinger Band | 7.78 |
| Percent B (%b) | 0.7 |
| BandWidth | 38.28 |
| MACD Line | 0.62 |
| MACD Signal Line | 0.65 |
| MACD Histogram | -0.0303 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.85 | ||||
| Resistance 3 (R3) | 10.87 | 10.74 | 10.76 | ||
| Resistance 2 (R2) | 10.74 | 10.61 | 10.72 | 10.73 | |
| Resistance 1 (R1) | 10.54 | 10.53 | 10.48 | 10.52 | 10.71 |
| Pivot Point | 10.41 | 10.41 | 10.37 | 10.39 | 10.41 |
| Support 1 (S1) | 10.21 | 10.28 | 10.15 | 10.19 | 9.99 |
| Support 2 (S2) | 10.08 | 10.20 | 10.06 | 9.97 | |
| Support 3 (S3) | 9.88 | 10.08 | 9.94 | ||
| Support 4 (S4) | 9.86 |
